A detailed history of Nuveen Asset Management, LLC transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 102,835 shares of GLUE stock, worth $873,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares
102,835
Previous 89,096 15.42%
Holding current value
$873,069
Previous $333,000 63.66%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.59 - $6.97 $49,323 - $95,760
13,739 Added 15.42%
102,835 $545,000
Q4 2023

Feb 14, 2024

SELL
$2.5 - $5.93 $161,867 - $383,949
-64,747 Reduced 42.09%
89,096 $503,000
Q3 2023

Nov 14, 2023

BUY
$4.78 - $7.22 $61,255 - $92,524
12,815 Added 9.09%
153,843 $736,000
Q2 2023

Aug 14, 2023

BUY
$4.53 - $8.4 $133,086 - $246,783
29,379 Added 26.31%
141,028 $966,000
Q1 2023

May 15, 2023

SELL
$5.95 - $8.21 $42,536 - $58,693
-7,149 Reduced 6.02%
111,649 $869,000
Q4 2022

Feb 14, 2023

SELL
$6.71 - $9.72 $92,926 - $134,612
-13,849 Reduced 10.44%
118,798 $905,000
Q3 2022

Nov 14, 2022

SELL
$7.17 - $12.16 $15,257 - $25,876
-2,128 Reduced 1.58%
132,647 $1.08 Million
Q2 2022

Aug 15, 2022

BUY
$6.15 - $14.99 $435,979 - $1.06 Million
70,891 Added 110.97%
134,775 $1.3 Million
Q1 2022

May 16, 2022

BUY
$10.36 - $20.41 $399,844 - $787,723
38,595 Added 152.62%
63,884 $802,000
Q4 2021

Feb 14, 2022

BUY
$16.28 - $27.15 $138,949 - $231,725
8,535 Added 50.94%
25,289 $444,000
Q3 2021

Nov 12, 2021

BUY
$18.59 - $42.21 $311,456 - $707,186
16,754 New
16,754 $373,000

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $397M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.